Literature DB >> 14727179

A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.

Kirsten M Timms1, Susanne Wagner, Mark E Samuels, Kristian Forbey, Howard Goldfine, Srikanth Jammulapati, Mark H Skolnick, Paul N Hopkins, Steve C Hunt, Donna M Shattuck.   

Abstract

Familial hypercholesterolemia results from mutations in the low-density lipoprotein (LDL) receptor or apolipoprotein B genes. We have previously reported the identification of a Utah autosomal-dominant hypercholesterolemia pedigree (kindred 1173) that did not show linkage to either of these loci (Hunt et al. 2000). Expansion of the pedigree and increased marker density within the region of interest have resulted in a multipoint LOD score of 9.6 and enabled us to decrease the size of the linked region to approximately 7.5 Mbp. In addition, we were able to identify additional families sharing the same microsatellite haplotype. While all haplotype carriers in kindred 1173 (K1173) are affected, the haplotype carriers within the newly identified families are unaffected, suggesting that the causal mutation in K1173 had occurred after divergence of these pedigrees from a common ancestor. Mutation screening of genes in the region identified a single nucleotide variant (G-->T) present on the K1173 haplotype that was not present on the same haplotype in the other kindreds. This variant results in a D374Y missense change in the gene PCSK9.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14727179     DOI: 10.1007/s00439-003-1071-9

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  11 in total

Review 1.  Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E.

Authors:  R W Mahley; Z S Ji
Journal:  J Lipid Res       Date:  1999-01       Impact factor: 5.922

Review 2.  Subtilases: the superfamily of subtilisin-like serine proteases.

Authors:  R J Siezen; J A Leunissen
Journal:  Protein Sci       Date:  1997-03       Impact factor: 6.725

3.  Amino acid difference formula to help explain protein evolution.

Authors:  R Grantham
Journal:  Science       Date:  1974-09-06       Impact factor: 47.728

4.  Understanding human disease mutations through the use of interspecific genetic variation.

Authors:  M P Miller; S Kumar
Journal:  Hum Mol Genet       Date:  2001-10-01       Impact factor: 6.150

5.  Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred.

Authors:  S C Hunt; P N Hopkins; K Bulka; M T McDermott; T L Thorne; B B Wardell; B R Bowen; D G Ballinger; M H Skolnick; M E Samuels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-04       Impact factor: 8.311

6.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

7.  A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32.

Authors:  M Varret; J P Rabès; B Saint-Jore; A Cenarro; J C Marinoni; F Civeira; M Devillers; M Krempf; M Coulon; R Thiart; M J Kotze; H Schmidt; J C Buzzi; G M Kostner; S Bertolini; M Pocovi; A Rosa; M Farnier; M Martinez; C Junien; C Boileau
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

8.  Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice.

Authors:  Kara N Maxwell; Raymond E Soccio; Elizabeth M Duncan; Ephraim Sehayek; Jan L Breslow
Journal:  J Lipid Res       Date:  2003-08-01       Impact factor: 5.922

9.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.

Authors:  S V Tavtigian; J Simard; J Rommens; F Couch; D Shattuck-Eidens; S Neuhausen; S Merajver; S Thorlacius; K Offit; D Stoppa-Lyonnet; C Belanger; R Bell; S Berry; R Bogden; Q Chen; T Davis; M Dumont; C Frye; T Hattier; S Jammulapati; T Janecki; P Jiang; R Kehrer; J F Leblanc; J T Mitchell; J McArthur-Morrison; K Nguyen; Y Peng; C Samson; M Schroeder; S C Snyder; L Steele; M Stringfellow; C Stroup; B Swedlund; J Swense; D Teng; A Thomas; T Tran; M Tranchant; J Weaver-Feldhaus; A K Wong; H Shizuya; J E Eyfjord; L Cannon-Albright; M Tranchant; F Labrie; M H Skolnick; B Weber; A Kamb; D E Goldgar
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

10.  The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.

Authors:  Nabil G Seidah; Suzanne Benjannet; Louise Wickham; Jadwiga Marcinkiewicz; Stephanie Belanger Jasmin; Stefano Stifani; Ajoy Basak; Annik Prat; Michel Chretien
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more
  90 in total

1.  PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.

Authors:  Estelle Rousselet; Jadwiga Marcinkiewicz; Jasna Kriz; Ann Zhou; Mary E Hatten; Annik Prat; Nabil G Seidah
Journal:  J Lipid Res       Date:  2011-04-25       Impact factor: 5.922

Review 2.  The genetic and molecular bases of monogenic disorders affecting proteolytic systems.

Authors:  I Richard
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

3.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Authors:  Ingrid K Kotowski; Alexander Pertsemlidis; Amy Luke; Richard S Cooper; Gloria L Vega; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-01-20       Impact factor: 11.025

Review 4.  Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.

Authors:  Nabil G Seidah; Annik Prat; Angela Pirillo; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

Review 5.  Genetic lipoprotein disorders and coronary atherosclerosis.

Authors:  Mahmoud Alawadhi; George Thanassoulis; Michel Marcil; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2005-05       Impact factor: 5.113

6.  APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.

Authors:  Ting Fu; YangYang Guan; Junjie Xu; Yan Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-05-09       Impact factor: 4.698

7.  Genetic variation and atherosclerosis.

Authors:  Erik Biros; Mirko Karan; Jonathan Golledge
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

8.  A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.

Authors:  Nidhi Gupta; Niels Fisker; Marie-Claude Asselin; Marie Lindholm; Christoph Rosenbohm; Henrik Ørum; Joacim Elmén; Nabil G Seidah; Ellen Marie Straarup
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

9.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

10.  Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.

Authors:  Hai Li; Bin Dong; Sahng Wook Park; Hyun-Sook Lee; Wei Chen; Jingwen Liu
Journal:  J Biol Chem       Date:  2009-08-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.